Risk Factors of Glucocorticoid-Induced Diabetes Mellitus in Systemic Lupus Erythematosus

Mojdeh Zabihi Yeganeh, Saeideh Sadeghi

Background: The aim of this study was to investigate the prevalence and associated factors of glucocorticoid-induced Diabetes mellitus (GIDM) in patients with systemic lupus erythematosus (SLE) under glucocorticoid therapy.

Methods: Patients with SLE who had received high-dose glucocorticoid therapy (prednisolone≥1 mg/kg/day) at Rasoul Akram and Firoozgar hospitals were recruited during 2006-2011.

Results: A total of 81 patients with SLE were evaluated. 21 patients (25.9%) of them developed GIDM after high-dose glucocorticoid therapy. Univariate analysis of data showed that old age, family history of diabetes mellitus (DM) and use of Mycophenolate mofetil were factors that would increase the likelihood of GIDM.

Conclusion: In summary, GIDM was developed among 25.9% of patients with SLE after high-dose glucocorticoid therapy. Old age, family history of DM and use of Mycophenolate mofetil were determined to be factors responsible for increasing the risk of developing GIDM.

Diabetes Mellitus; Glucocorticoid; Systemic Lupus Erythematosus; Risk factor

Lipsky PE, Diamond B. Autoimmunity and autoimmune disease. In: Braunwald E, Fauci A, Kasper D, Hauser SL, Longo DL, Jameson JL, et al, editors. Harrison’s principle of internal medicine. 17th ed. New York: McGraw-Hill. 2008;2071-74.

Hannahs Hahn B. Systemic lupus erythematosus In: Braunwald E, Fauci A, Kasper D, Hauser SL, Longo DL, Jameson JL, et al, editors. Harrison’s principle of internal medicine 17th ed. New York: McGraw-Hill, 2008;2075-83.

Utz PJ. Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus. Lupus. 2004;13:304-11.

liu CC, Manzi S, Danchenko N, Ahearn JM. New advances in measurement of complement activation: lessons of systemic lupus erythematosus. Curr Rheumatol Rep. 2004;6:375-81.

Manzi S, Ahearn JM, Salmon J. New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus. Lupus. 2004;13:298-303.

Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15:308.

Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469-74.

Tryfon S, Papanas N. Corticosteroid-induced diabetes in patients with chronic obstructive pulmonary disease. Clin Pulm Med. 2008;15:127-31.

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-801.

Curtis JR, Westfall AO, Allison J. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420-6.

You Jung L, Kwang-Hoon J, Se-jin K. Prevalence and Risk Factors of Glucocorticoid-Induced Diabetes Mellitus in Patients with Systemic Lupus Erythematosus. Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. 2010.

Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J. 2004;49(4):139-41.

Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105(2):54-7.

Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469-74.

Zeng YJ, Zeng FQ, Dai L, Yang C, Lin BZ, Zheng DH, et al. Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus. Lupus. 2010;19(11):1344-50.

Takuya I, Yoshiyuki K, , Yutaka N. Steroid-Induced Diabetes Mellitus and Related Risk Factors in Patients With Neurologic Disease. Pharmacotherapy. 2004;24(4).

Clore JN. Adrenocorticotropin and cortisol-induced changes in urinary sodium and potassium excretion in man: effects of spironolactone and RU486. J Clin Endocrinol Metab. 1988;67:82.

Spenney JG, Eure CA , Kreisberg RA . Hyperglycemic, hyperosmolar, nonketoacidotic diabetes. A complication of steroid and immunosuppressive theraphy. Diabetes. 1969;18:107-10.

King JK, Hahn BH. Systemic lupus erythematosus:modern strategies for management:a moving target. Best Pract Res Clin Rheumatol. 2007;21:971-98.

Forsythe J. Tacrolimus and mycophenolate mofetil in cadavericrenal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. Transplant Proc. 1999;31:69-71.

Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000;47:215–45.


  • There are currently no refbacks.